Analyst cites broad-based sales growth and share gains in heart-valve replacements as key drivers for the upgrade.
Edwards Lifesciences (EW) received an analyst upgrade following a robust second-quarter performance, with shares rising early Friday. Leerink Partners analyst Mike Kratky highlighted the company’s share gains in transcatheter aortic and mitral/tricuspid heart-valve replacements, along with upcoming clinical readouts and underappreciated tailwinds as reasons for the upgrade.
The stock had previously advanced in April after beating first-quarter sales and earnings expectations. The latest upgrade reflects sustained momentum in key product lines and operational strength, reinforcing its position in the large-cap medtech sector.
Edwards Lifesciences’ stock moved higher in early trading, reflecting investor confidence in the company’s growth trajectory and market leadership in structural heart devices.